Biopharma | May 13, 2026
Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Around 2,000 runners participated in the awareness run organised during World Retinoblastoma Awareness Week
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Dr Reddy has made remarkable contributions towards advancing cancer care through clinical excellence, pioneering research, academic mentorship, and compassionate healing
Healthcare operations veteran with over 23 years of experience to lead key initiatives across South India
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The event will bring together industrial leaders, technology providers, and policymakers to discuss real-world Industrial AI applications in Bangalore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
